[Oxiconazole cream versus ketoconazole cream. A prospective, randomized, double-blind, multicenter study in the treatment of inguinocrural dermatophytoses]. 1996

B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
Service de Dermatologie, Hôpital Robert-Debré, Reims.

BACKGROUND The aim of this study was to compare oxiconazole, 1 p. 100 cream, with ketoconazole, 2 p. 100 cream, applied once-daily, in the treatment of tinea cruris. METHODS A prospective, randomized, double-blind trial was performed in 8 dermatology departments on two parallel groups in patients having this type of mycosis confirmed by mycological examination. RESULTS The efficacy was analyzed in 66 out of the 79 patients included in the study (36 patients treated with oxiconazole, 30 with ketoconazole). At Day 14, a first assessment was made and 77.1 p. 100 of the patients treated with oxiconazole had been cured; this result was significantly better (p < 0.05) than that obtained with ketoconazole (51.7 p. 100 of cured patients). At Day 21, after a further week of treatment, both treatments were efficient with statistically non-different results between the two groups: 97.2 p. 100 of the patients treated with oxiconazole, versus 86.7 p. 100 with ketoconazole. Thus, a greater rapidity of action of oxiconazole was observed. No correlation was detected between the ratio of cured patients and the duration of the mycosis. The safety was assessed in 74 patients. No adverse effects were reported for the patients treated with oxiconazole, whereas 9 patients treated with ketoconazole experienced contact sensitization reactions and irritant skin reactions due to the application of the product. The difference between the two groups of treatment was statistically greatly significant (p < 0.001). Furthermore, acceptance of the drug on the part of the patient was better (p < 0.05) with oxiconazole. CONCLUSIONS After 3 weeks of topical treatment oxiconazole has revealed itself to be as efficient as ketoconazole, but it seems more rapidly efficient and better tolerated than ketoconazole.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D007654 Ketoconazole Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Nizoral,R-41400,R41,400,R41400,R 41400
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003881 Dermatomycoses Superficial infections of the skin or its appendages by any of various fungi. Skin Diseases, Fungal,Dermatomycosis,Dermatophyte Infection,Fungal Skin Diseases
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006119 Groin The external junctural region between the lower part of the abdomen and the thigh. Groins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
January 1983, Dermatologica,
B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
January 1988, The Pediatric infectious disease journal,
B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
November 1988, Journal of the American Academy of Dermatology,
B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
January 2005, Journal of drugs in dermatology : JDD,
B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
June 2004, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology,
B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
November 1987, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia,
B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
January 1981, Arzneimittel-Forschung,
B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
May 1997, Zhonghua nei ke za zhi,
B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
March 2007, Journal of the European Academy of Dermatology and Venereology : JEADV,
B Kalis, and E Grosshans, and O Binet, and J B Garrel, and G Grossetête, and G Jeanpierre, and Y Privat, and J M Sonneck, and P Souteyrand
March 1993, The American journal of medicine,
Copied contents to your clipboard!